Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (10): 1889-1892.doi: 10.3969/j.issn.1673-8225.2011.10.040

Previous Articles     Next Articles

Autologous hematopoietic stem cell transplantation and allogeneic umbilical cord mesenchymal stem cell transplantation in the treatment of neural degenerative diseases

Wang Li-ming1, Zhou Jian-jun1, Bai Wen1, Bai Bing1, Li Jian-jun1, Wang Li-hua2, Liu Yong-jun2   

  1. 1Cell Therapy Center, The 323 Hospital of Chinese PLA, Xi’an   710054, Shaanxi Province, China
    2National State Key Laboratory of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin   300020, China
  • Received:2010-10-08 Revised:2010-11-12 Online:2011-03-05 Published:2011-03-05
  • Contact: Liu Yong-jun, National State Key Laboratory of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin 300020, China andyliuliu2001@ yahoo.com.cn
  • About author:Wang Li-ming★, Master, Chief physician, Cell Therapy Center, The 323 Hospital of Chinese PLA, Xi’an 710054, Shaanxi Province, China wanglm@fmmu.edu.cn

PDF

639

Abstract:

BACKGROUND: Autologous hematopoietic stem cell transplantation (AHSCT) and allogeneic umbilical cord mesenchymal stem cell (UC-MSC) technology are applied in clinic, trying to find a new feasible method of the treatment of neural degenerative disease.
OBJECTIVE: To study the feasibility of AHSCT CD34+ and UC-MSC in the treatment of neural degenerative disease.
METHODS: A total of 21 patients with neural degenerative disease were selected, including 15 cases with motor neuron disease (MND), 6 cases with spinocerebellar ataxia. A volume of 4 mL UC-MSC or AHSCT solution was injected into subarachnoid space through lumbar puncture; the number of injected cells was 1.0×107 each time. At 3 months following stem cells therapy, all patients were scored.
RESULTS AND CONCLUSION: In 15 patients with MND, the total effective rate was 80%. There were significant differences between the acute lateral sclerosis (ALS) functional rating scale and the self-assessment questionnaire scores before and after treatment (P < 0.05). Six cases with spinal cerebellar ataxia underwent international cooperative ataxiarating scale (ICARS). The grade of disease condition was reduced in 4 cases; the total effective rate was 77%. Four of the 21 cases had mild intracranial hypotension headache (after lumbar puncture). Two of the 14 patients with the treatment of UC-MSC had transient fever at 2 hours after treatment. The remaining patients had no significant adverse reactions after treatment. The results primarily demonstrated that the AHSCT and UC-MSC have a positive clinical effect, which are safe and feasible in the treatment of neural degenerative disease.

CLC Number: